151 related articles for article (PubMed ID: 27177757)
1. Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy.
Schepisi G; Santoni M; Massari F; Gurioli G; Salvi S; Conteduca V; Montironi R; De Giorgi U
BioDrugs; 2016 Aug; 30(4):263-73. PubMed ID: 27177757
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint inhibitors in bladder and renal cancers: results and perspectives.
Aoun F; Kourie HR; Sideris S; Roumeguère T; van Velthoven R; Gil T
Immunotherapy; 2015; 7(12):1259-71. PubMed ID: 26595284
[TBL] [Abstract][Full Text] [Related]
3. Combination cancer immunotherapy and new immunomodulatory targets.
Mahoney KM; Rennert PD; Freeman GJ
Nat Rev Drug Discov; 2015 Aug; 14(8):561-84. PubMed ID: 26228759
[TBL] [Abstract][Full Text] [Related]
4. The State of Immune Checkpoint Inhibition in Urothelial Carcinoma: Current Evidence and Future Areas of Exploration.
Campbell MT; Siefker-Radtke AO; Gao J
Cancer J; 2016; 22(2):96-100. PubMed ID: 27111904
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint blocking antibodies in cancer immunotherapy.
Kyi C; Postow MA
FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Therapies in Prostate Cancer.
Goswami S; Aparicio A; Subudhi SK
Cancer J; 2016; 22(2):117-20. PubMed ID: 27111907
[TBL] [Abstract][Full Text] [Related]
7. Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?
Sundararajan S; Vogelzang NJ
Future Oncol; 2015; 11(16):2299-306. PubMed ID: 26260808
[TBL] [Abstract][Full Text] [Related]
8. Recent developments and future challenges in immune checkpoint inhibitory cancer treatment.
Koster BD; de Gruijl TD; van den Eertwegh AJ
Curr Opin Oncol; 2015 Nov; 27(6):482-8. PubMed ID: 26352539
[TBL] [Abstract][Full Text] [Related]
9. Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors.
Day D; Hansen AR
BioDrugs; 2016 Dec; 30(6):571-584. PubMed ID: 27848165
[TBL] [Abstract][Full Text] [Related]
10. The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma.
Wang SD; Li HY; Li BH; Xie T; Zhu T; Sun LL; Ren HY; Ye ZM
Int Immunopharmacol; 2016 Sep; 38():81-9. PubMed ID: 27258185
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy: The Wave of the Future in Bladder Cancer?
Petrylak DP
Clin Genitourin Cancer; 2017 Jun; 15(3S):S3-S17. PubMed ID: 28633756
[TBL] [Abstract][Full Text] [Related]
12. The PD-1/PD-L1 axis in the pathogenesis of urothelial bladder cancer and evaluating its potential as a therapeutic target.
Bardoli AD; Afshar M; Viney R; Foster M; Porfiri E; Zarkar A; Stevenson R; James ND; Bryan RT; Patel P
Future Oncol; 2016 Mar; 12(5):595-600. PubMed ID: 26880382
[No Abstract] [Full Text] [Related]
13. Targeting the immune system to treat lung cancer: rationale and clinical experience.
Guibert N; Delaunay M; Mazières J
Ther Adv Respir Dis; 2015 Jun; 9(3):105-20. PubMed ID: 25827132
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint therapy for non-small-cell lung cancer: an update.
Xia B; Herbst RS
Immunotherapy; 2016; 8(3):279-98. PubMed ID: 26860624
[TBL] [Abstract][Full Text] [Related]
15. Programmed death 1 and its ligands do not limit experimental foreign antigen-induced immune complex glomerulonephritis.
Ooi JD; Li M; Kourkoutzelos K; Yagita H; Azuma M; Holdsworth SR; Kitching AR
Nephrology (Carlton); 2015 Dec; 20(12):892-8. PubMed ID: 26043977
[TBL] [Abstract][Full Text] [Related]
16. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapies for bladder cancer: a new hope.
Fakhrejahani F; Tomita Y; Maj-Hes A; Trepel JB; De Santis M; Apolo AB
Curr Opin Urol; 2015 Nov; 25(6):586-96. PubMed ID: 26372038
[TBL] [Abstract][Full Text] [Related]
18. Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer.
Howell M; Lee R; Bowyer S; Fusi A; Lorigan P
Lung Cancer; 2015 May; 88(2):117-23. PubMed ID: 25776466
[TBL] [Abstract][Full Text] [Related]
19. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
Garon EB
Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
[TBL] [Abstract][Full Text] [Related]
20. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.
Swaika A; Hammond WA; Joseph RW
Mol Immunol; 2015 Oct; 67(2 Pt A):4-17. PubMed ID: 25749122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
